Over the last 21 years, insiders at Dynavax Technologies have traded over 196,839,440$ worth of Dynavax Technologies stock and bought 2,463,112 units worth 11,318,051$ . The most active insiders traders include Andrew A. F. Hack、Partners L P/Ilbiotechnolog...、James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of 1,533,390$. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth 43,127$.
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Dynavax Technologies executives and other stock owners filed with the SEC include: